The side effect management of pezopanib is to reduce or discontinue the dosage according to the severity of the reaction, and the dosage is adjusted according to the individual tolerance, and the dosage is gradually increased or decreased by the magnitude of 200 mg to control the adverse reaction. The primary indication for pazopanib is the treatment of patients with advanced renal cell carcinoma or first-line renal cell carcinoma who have previously received cytokine therapy, pazotinib should be used with caution in patients with mild or moderate hepatic impairment, and pazopanib is not recommended for severe hepatic impairment. Side effects include: exfoliative rash, hypoalbuminemia, left ventricular insufficiency, hiccups (hiccups), cough and bronchial hemorrhage, abnormal ear, nose, and throat examinations, cholesterol abnormalities, and a variety of musculoskeletal and connective tissue disorders, which may require a reduction in the dosage of pezopanib or discontinuation of pezopanib; infrequent side effects, such as gastric hemorrhage, cerebral infarction and inflammation of the peritoneal membrane, and skin ulcers require discontinuation of pezopanib. Contraindications: hypersensitivity to pezopanib is contraindicated. If there is any discomfort when using Pezopanib, it is recommended to go to the hospital for a clear diagnosis and treatment in time to avoid delaying the condition.